Evolution of the Average Target: Altimmune, Inc.

Evolution of the Average Target - Altimmune, Inc.

Evolution of the Target Price: Altimmune, Inc.

Evolution of the Target Price - Altimmune, Inc.

Changes in Analyst Recommendations: Altimmune, Inc.

a77a8927c7659.rNPbtezjDzAYXioPJgs-_FnDXxBf2kH4PsbTj09wtwc.wr6rwoCkO1xtallgY2xGqDugCkcSryu6V_-23C47z1j-pJLtrpA8di8wZw~9049f6dd3356158f4a6dfb543ac1ceda
11-13 B. Riley Adjusts Altimmune Price Target to $11 From $13, Maintains Buy Rating MT
06-22 Leerink Partners Initiates Altimmune at Outperform With $10 Price Target MT
04-24 Goldman Sachs Upgrades Altimmune to Neutral From Sell, Adjusts Price Target to $2.50 From $1 MT
03-19 Truist Initiates Altimmune at Buy With $12 Price Target MT
03-06 B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating MT
01-28 Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target MT
25-08-13 UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating MT
25-08-13 B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating MT
25-02-28 William Blair Initiates Altimmune at Market Perform MT
25-01-08 Stifel Initiates Altimmune at Buy With $18 Price Target MT
24-11-12 UBS Initiates Altimmune at Buy With $26 Price Target MT
24-04-29 Altimmune Shares Decline After Guggenheim Downgrade MT
24-04-29 Guggenheim Downgrades Altimmune to Neutral From Buy MT
24-01-17 B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating MT
23-11-09 B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating MT
23-08-14 HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating MT
23-08-11 B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating MT
23-08-10 B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating MT
23-03-22 Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20 MT
23-01-20 HC Wainwright Reiterates Altimmune at Buy With $50 Price Target MT
23-01-18 Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating MT
22-12-01 Goldman Sachs Initiates Altimmune at Buy With $20 Price Target MT
22-11-11 JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating MT
22-09-28 Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight CI
22-09-16 Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+947.01%
+40.11%
+15.84%
+7.38%
+14.09%
+17.81%
+29.86%
+64.61%
+18.88%
+58.03%
Average +121.36%
Weighted average by Cap. +27.97%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.560USD
Average target price
16.33USD
Spread / Average Target
+947.01%
High Price Target
26.00USD
Spread / Highest target
+1,566.67%
Low Price Target
11.00USD
Spread / Lowest Target
+605.13%

Analyst Consensus Detail

Analyst consensus - Altimmune, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Altimmune, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Altimmune, Inc.
  1. Stock Market
  2. Stocks
  3. ALT Stock
  4. Consensus Altimmune, Inc.